- Home
- NTWK vs UNCY Comparison
NTWK vs UNCY Comparison
Compare NTWK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTWK
- UNCY
- Stock Information
- Founded
- NTWK 1997
- UNCY 2016
- Country
- NTWK United States
- UNCY United States
- Employees
- NTWK N/A
- UNCY N/A
- Industry
- NTWK Computer Software: Prepackaged Software
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- NTWK Technology
- UNCY Health Care
- Exchange
- NTWK Nasdaq
- UNCY Nasdaq
- Market Cap
- NTWK 31.1M
- UNCY 31.9M
- IPO Year
- NTWK 1998
- UNCY 2021
- Fundamental
- Price
- NTWK $2.69
- UNCY $0.46
- Analyst Decision
- NTWK
- UNCY Strong Buy
- Analyst Count
- NTWK 0
- UNCY 4
- Target Price
- NTWK N/A
- UNCY $5.50
- AVG Volume (30 Days)
- NTWK 21.9K
- UNCY 1.9M
- Earning Date
- NTWK 11-13-2024
- UNCY 11-13-2024
- Dividend Yield
- NTWK N/A
- UNCY N/A
- EPS Growth
- NTWK N/A
- UNCY N/A
- EPS
- NTWK 0.06
- UNCY N/A
- Revenue
- NTWK $61,749,408.00
- UNCY N/A
- Revenue This Year
- NTWK N/A
- UNCY N/A
- Revenue Next Year
- NTWK N/A
- UNCY N/A
- P/E Ratio
- NTWK $42.79
- UNCY N/A
- Revenue Growth
- NTWK 14.50
- UNCY N/A
- 52 Week Low
- NTWK $1.94
- UNCY $0.20
- 52 Week High
- NTWK $3.34
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- NTWK 35.05
- UNCY 48.64
- Support Level
- NTWK $2.95
- UNCY $0.41
- Resistance Level
- NTWK $3.23
- UNCY $0.55
- Average True Range (ATR)
- NTWK 0.16
- UNCY 0.06
- MACD
- NTWK -0.04
- UNCY -0.01
- Stochastic Oscillator
- NTWK 11.48
- UNCY 23.47
About NTWK NetSol Technologies Inc. Common Stock
NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions. Its products and services include NFS Ascent, NFS Digital, Leasepak Cloud, Business consultancy, and information security services among others. The firm has North America, Europe, and Asia-Pacific segments, of which the majority of the revenue is derived from Asia-Pacific. It derives revenue from licensing, customization, enhancements, and maintenance of its financial applications. The company promotes and sells its products under the Netsol financial suite.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.